Covid19
Commented by Juliane Zielonka on September 22nd, 2022 | 11:58 CEST
Cardiol Therapeutics, Apple, Nel - Crisis-proof shares, despite inflation
Heart fluttering, pulse racing among investors, share prices highly volatile due to FED measures. Inflation and recessionary times are brutal for investors in the capital market. Three candidates have the potential to become profitable long-term investments: Cardiol Therapeutics, Apple and Nel. Cardiol Therapeutics fills the gap in the pharmaceutical market for the treatment of the heart disease, myocarditis. Apple is increasingly focusing on monitoring heart health, as cardiovascular disease is one of the leading causes of death in industrialized nations. In turn, these nations are struggling with extremely high energy prices. No wonder, then, that the Norwegian government is financially supporting the Company Nel to produce green hydrogen as quickly as possible...
Read
Commented by Stefan Feulner on September 22nd, 2022 | 11:32 CEST
BioNTech, XPhyto, Valneva - It is over!
In an interview with the television station "CBS", the most powerful man in the world, US President Joe Biden, declared the pandemic over. While people in Germany have to wear face masks to the Oktoberfest in local and long-distance transport and then blare the latest hits from Mallorca in the marquee, without masks, of course, outside the former growth engine of Europe, relaxation seems to be setting in regarding COVID-19. A blow to the global vaccine industry! Meanwhile, a new market is growing unnoticed in the healthcare industry that could trigger a lasting trend in the near future.
Read
Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST
BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?
The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.
Read
Commented by Carsten Mainitz on July 28th, 2022 | 13:35 CEST
BioNTech, Defence Therapeutics, Valneva - Will the fall bring a new boost?
Officials expect the Corona pandemic to intensify sharply in the fall. Already, the number of cases is rising, as is the number of hospitalizations. To be better equipped against the currently prevalent Omicron variant, BioNTech/Pfizer have specifically adapted the Comirnaty vaccine to it. Valneva's recently approved vaccine also provides good protection against Omicron through a broader immune response to its inactivated vaccine. Also involved in vaccine development is the Canadian company Defence Therapeutics. It is currently attracting attention with its cancer-fighting developments and could become a real gem.
Read
Commented by Nico Popp on July 21st, 2022 | 11:24 CEST
Time is of the essence! Bavarian Nordic, XPhyto, Valneva
Resourceful investors always bet on corresponding stocks when new pathogens or disease patterns become known. BioNTech was one of the early movers in the case of COVID-19, but so were several other stocks that are now unknown again. Even for monkeypox, there have long been stocks that have profited - for example, the share of smallpox vaccine manufacturer Bavarian Nordic which recently rose sharply. We explain the hype around pharmaceutical stocks and outline where there could still be potential now.
Read
Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST
Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?
The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.
Read
Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST
Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!
For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?
Read
Commented by Nico Popp on May 5th, 2022 | 11:52 CEST
Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva
Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.
Read